BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 22613413)

  • 1. An efficacy analysis for nasopharyngeal carcinoma screening of different screening intervals.
    Rao DP; Gu J; Meng XH; Zhang Q; Fu MQ; Liu Y; Chen F; Cao SM; Hong MH; Liu Q
    J Int Med Res; 2012; 40(2):525-36. PubMed ID: 22613413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Cost-effectiveness evaluation of seven screening strategies for nasopharyngeal carcinoma].
    Rao DP; Liu Q; Cao SM
    Zhonghua Zhong Liu Za Zhi; 2012 Jul; 34(7):549-53. PubMed ID: 22967476
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Establishment of VCA and EBNA1 IgA-based combination by enzyme-linked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma: a two-stage design with a preliminary performance study and a mass screening in southern China.
    Liu Y; Huang Q; Liu W; Liu Q; Jia W; Chang E; Chen F; Liu Z; Guo X; Mo H; Chen J; Rao D; Ye W; Cao S; Hong M
    Int J Cancer; 2012 Jul; 131(2):406-16. PubMed ID: 21866545
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
    Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
    BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Early detection of nasopharyngeal carcinoma using IgA anti-EBNA1 + VCA-p18 serology assay.
    Romdhoni AC; Wiqoyah N; Kentjono WA
    Ear Nose Throat J; 2014 Mar; 93(3):112-5. PubMed ID: 24652560
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a semi-quantitative ELISA for IgA antibody against Epstein-Barr virus capsid antigen in the serological diagnosis of nasopharyngeal carcinoma.
    Chen H; Chi P; Wang W; Li L; Luo Y; Fu J; Zhang L; Liu W
    Int J Infect Dis; 2014 Aug; 25():110-5. PubMed ID: 24878579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific IgA antibody to Epstein-Barr viral capsid antigen: a better marker for screening nasopharyngeal carcinoma than EBV-DNA detection by polymerase chain reaction.
    Kantakamalakul W; Chongkolwatana C; Naksawat P; Muangsomboon S; Sukpanichnant S; Chongvisal S; Metheetrairat C; Kositanont U; Puthavathana P
    Asian Pac J Allergy Immunol; 2000 Dec; 18(4):221-6. PubMed ID: 11316043
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nasopharyngeal Epstein-Barr Virus Load: An Efficient Supplementary Method for Population-Based Nasopharyngeal Carcinoma Screening.
    Chen Y; Zhao W; Lin L; Xiao X; Zhou X; Ming H; Huang T; Liao J; Li Y; Zeng X; Huang G; Ye W; Zhang Z
    PLoS One; 2015; 10(7):e0132669. PubMed ID: 26151639
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rta-IgG as a biomarker for diagnosis and post treatment prognostic of nasopharyngeal carcinoma.
    Xu XF; Lu RQ; Xiao R; Zhou L; Zhao XM; Hu XC; Gao X; Guo L
    Cancer Biomark; 2016; 16(3):467-76. PubMed ID: 27062704
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Comparison of incidence of nasopharyngeal carcinoma in populations with different fluctuation modes of immunoglobulin A antibody levels against Epstein-Barr virus capsid antigen].
    Chen F; Liu K; Huang QH; Liu ZW; Cao SM
    Zhonghua Yu Fang Yi Xue Za Zhi; 2012 Feb; 46(2):125-8. PubMed ID: 22490193
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interval cancers in nasopharyngeal carcinoma screening: comparing two screening intervals after a negative initial screening result.
    Chen F; Huang QH; Fang F; Liu ZW; Liu K; Xie SH; Liu Q; Hong MH; Liao ZE; Ye WM; Zeng YX; Cao SM
    J Med Screen; 2012 Dec; 19(4):195-200. PubMed ID: 23258840
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epidemiological analysis of nasopharyngeal carcinoma in the central region of Japan during the period from 1996 to 2005.
    Kimura Y; Suzuki D; Tokunaga T; Takabayashi T; Yamada T; Wakisaka N; Yoshizaki T; Murata H; Miwa K; Shoujaku H; Watanabe Y; Yamada N; Ito Y; Yuta A; Takeuchi K; Hosokawa S; Mineta H; Hasegawa Y; Fujimoto Y; Nakashima T; Fujieda S
    Auris Nasus Larynx; 2011 Apr; 38(2):244-9. PubMed ID: 20817430
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma.
    Hu B; Hong G; Li Z; Xu J; Zhu Z; Li L
    Biotechnol Appl Biochem; 2007 May; 47(Pt 1):59-69. PubMed ID: 17129209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two Epstein-Barr virus-related serologic antibody tests in nasopharyngeal carcinoma screening: results from the initial phase of a cluster randomized controlled trial in Southern China.
    Liu Z; Ji MF; Huang QH; Fang F; Liu Q; Jia WH; Guo X; Xie SH; Chen F; Liu Y; Mo HY; Liu WL; Yu YL; Cheng WM; Yang YY; Wu BH; Wei KR; Ling W; Lin X; Lin EH; Ye W; Hong MH; Zeng YX; Cao SM
    Am J Epidemiol; 2013 Feb; 177(3):242-50. PubMed ID: 23255783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Combined detection of Epstein-Barr virus antibodies for serodiagnosis of nasopharyngeal carcinoma].
    Cai YL; Zheng YM; Wang W; Wei Y; Shen XX; Cheng JR; Wu YS; Gao JQ; Zhong WM; Li J
    Nan Fang Yi Ke Da Xue Xue Bao; 2010 Dec; 30(12):2746-8. PubMed ID: 21177196
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significance of plasma IgA and IgG antibodies to Epstein-Barr virus early and viral capsid antigens in Thai nasopharyngeal carcinoma.
    Tiwawech D; Srivatanakul P; Karaluk A; Ishida T
    Asian Pac J Cancer Prev; 2003; 4(2):113-8. PubMed ID: 12875623
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong.
    Ling W; Cao SM; Huang QH; Li YH; Deng MQ
    Ai Zheng; 2009 Jan; 28(1):57-9. PubMed ID: 19448418
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantification of Epstein-Barr virus DNA load in nasopharyngeal brushing samples in the diagnosis of nasopharyngeal carcinoma in southern China.
    Zheng XH; Lu LX; Li XZ; Jia WH
    Cancer Sci; 2015 Sep; 106(9):1196-201. PubMed ID: 26082292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Noninvasive diagnosis of nasopharyngeal carcinoma: nasopharyngeal brushings reveal high Epstein-Barr virus DNA load and carcinoma-specific viral BARF1 mRNA.
    Stevens SJ; Verkuijlen SA; Hariwiyanto B; Harijadi ; Paramita DK; Fachiroh J; Adham M; Tan IB; Haryana SM; Middeldorp JM
    Int J Cancer; 2006 Aug; 119(3):608-14. PubMed ID: 16572427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.